A detailed history of Capital Analysts, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Capital Analysts, LLC holds 13,883 shares of BMY stock, worth $789,109. This represents 0.03% of its overall portfolio holdings.

Number of Shares
13,883
Previous 9,531 45.66%
Holding current value
$789,109
Previous $396,000 81.31%
% of portfolio
0.03%
Previous 0.02%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$39.66 - $51.75 $172,600 - $225,216
4,352 Added 45.66%
13,883 $718,000
Q2 2024

Aug 14, 2024

BUY
$40.25 - $52.99 $4,870 - $6,411
121 Added 1.29%
9,531 $396,000
Q1 2024

May 14, 2024

BUY
$47.98 - $54.4 $60,934 - $69,088
1,270 Added 15.6%
9,410 $510,000
Q4 2023

Jan 30, 2024

SELL
$48.48 - $57.85 $106,704 - $127,327
-2,201 Reduced 21.28%
8,140 $418,000
Q3 2023

Nov 13, 2023

SELL
$57.89 - $64.73 $30,913 - $34,565
-534 Reduced 4.91%
10,341 $600,000
Q2 2023

Aug 11, 2023

SELL
$63.71 - $70.74 $29,688 - $32,964
-466 Reduced 4.11%
10,875 $696,000
Q1 2023

May 05, 2023

SELL
$65.71 - $74.53 $22,472 - $25,489
-342 Reduced 2.93%
11,341 $786,000
Q4 2022

Feb 08, 2023

BUY
$68.48 - $81.09 $22,803 - $27,002
333 Added 2.93%
11,683 $840,000
Q3 2022

Nov 14, 2022

BUY
$0.13 - $76.84 $52 - $31,043
404 Added 3.69%
11,350 $807,000
Q2 2022

Aug 12, 2022

BUY
$72.62 - $79.98 $7,552 - $8,317
104 Added 0.96%
10,946 $843,000
Q1 2022

May 12, 2022

BUY
$61.48 - $73.72 $113,676 - $136,308
1,849 Added 20.56%
10,842 $791,000
Q4 2021

Feb 10, 2022

BUY
$53.63 - $62.52 $47,891 - $55,830
893 Added 11.02%
8,993 $561,000
Q3 2021

Nov 04, 2021

BUY
$59.17 - $69.31 $67,276 - $78,805
1,137 Added 16.33%
8,100 $479,000
Q2 2021

Nov 15, 2021

SELL
$61.91 - $67.42 $121,776 - $132,615
-1,967 Reduced 22.03%
6,963 $465,000
Q2 2021

Aug 05, 2021

BUY
$61.91 - $67.42 $112,057 - $122,030
1,810 Added 25.42%
8,930 $596,000
Q1 2021

May 17, 2021

BUY
$59.34 - $66.74 $185,140 - $208,228
3,120 Added 78.0%
7,120 $449,000
Q4 2020

Feb 16, 2021

SELL
$57.74 - $65.43 $26,618 - $30,163
-461 Reduced 10.33%
4,000 $248,000
Q3 2020

Nov 12, 2020

BUY
$57.43 - $63.64 $459 - $509
8 Added 0.18%
4,461 $269,000
Q2 2020

Aug 07, 2020

BUY
$54.82 - $64.09 $26,478 - $30,955
483 Added 12.17%
4,453 $262,000
Q1 2020

May 08, 2020

SELL
$46.4 - $67.43 $15,590 - $22,656
-336 Reduced 7.8%
3,970 $221,000
Q4 2019

Feb 12, 2020

BUY
$49.21 - $64.19 $4,478 - $5,841
91 Added 2.16%
4,306 $276,000
Q3 2019

Nov 12, 2019

SELL
$42.77 - $50.71 $2,095 - $2,484
-49 Reduced 1.15%
4,215 $213,000
Q2 2019

Aug 13, 2019

BUY
$44.62 - $49.34 $30,877 - $34,143
692 Added 19.37%
4,264 $193,000
Q1 2019

May 13, 2019

BUY
$45.12 - $53.8 $20,439 - $24,371
453 Added 14.52%
3,572 $170,000
Q2 2018

Aug 03, 2018

BUY
$50.53 - $62.98 $22,738 - $28,341
450 Added 16.86%
3,119 $0
Q1 2018

May 14, 2018

BUY
$59.92 - $68.98 $28,941 - $33,317
483 Added 22.1%
2,669 $169,000
Q4 2017

Feb 14, 2018

BUY
$59.94 - $65.35 $106,213 - $115,800
1,772 Added 428.02%
2,186 $134,000
Q4 2017

Feb 12, 2018

SELL
$59.94 - $65.35 $128,211 - $139,783
-2,139 Reduced 83.78%
414 $74,000
Q3 2017

Nov 06, 2017

BUY
$55.23 - $63.74 $141,002 - $162,728
2,553
2,553 $163,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $121B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Capital Analysts, LLC Portfolio

Follow Capital Analysts, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Analysts, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Capital Analysts, LLC with notifications on news.